Company attributes 276 percent revenue growth in 2017 to GPS Cancer™
and advanced oncology solutions
CULVER CITY, Calif.--(BUSINESS WIRE)--
NantHealth,
Inc. (NASDAQ-GS: NH), a next-generation, evidence-based, personalized
healthcare company, announced today a ranking of 304 on Deloitte’s
Technology Fast 500™, a ranking of the 500 fastest growing technology,
media, telecommunications, life sciences and energy tech companies in
North America.
NantHealth’s founder and chief executive officer, Patrick Soon-Shiong,
MD, credits GPS Cancer™ adoption, the company’s ability to offer
the latest software technology that supports advancements in precision
medicine and the company’s 276 percent revenue growth for the
significant accomplishment. Dr. Soon-Shiong said, "Over the years we’ve
seen significant adoption of technology solutions to advance healthcare,
and for NantHealth to be a top contender in the health technology space
is a testament to GPS Cancer and our best-in-class oncology solutions.
We’re looking forward to our committed journey toward achieving
precision medicine and we are honored to be recognized by Deloitte."
“The Deloitte 2017 North America Technology Fast 500 winners underscore
the impact of technological innovation and world class customer service
in driving growth, in a fiercely competitive environment,” said Sandra
Shirai, vice chairman, Deloitte Consulting LLP and U.S. technology,
media and telecommunications leader. “These companies are on the cutting
edge and are transforming the way we do business. We extend our sincere
congratulations to all the winners for achieving remarkable growth while
delivering new services and experiences for their customers.”
“Emerging growth companies are powering innovation in the broader
economy. The growth rates delivered by the companies on this year’s
North America Technology Fast 500 ranking are a bright spot for the
capital markets and a strong indicator that the emerging growth
technology sector will continue to deliver a strong return on
investment,” said Heather Gates, national managing director of Deloitte
& Touche LLP’s emerging growth company practice. “Deloitte is dedicated
to supporting the best and brightest companies of the future in the
emerging growth company sector. We are proud to acknowledge the
significant accomplishments of this year’s Fast 500 winners.”
About Deloitte’s 2017 Technology Fast 500™
Deloitte’s Technology Fast 500 provides a ranking of the fastest growing
technology, media, telecommunications, life sciences and energy tech
companies — both public and private — in North America. Technology Fast
500 award winners are selected based on percentage fiscal year revenue
growth from 2013 to 2016.
In order to be eligible for Technology Fast 500 recognition, companies
must own proprietary intellectual property or technology that is sold to
customers in products that contribute to a majority of the company’s
operating revenues. Companies must have base-year operating revenues of
at least $50,000 USD, and current-year operating revenues of at least $5
million USD. Additionally, companies must be in business for a minimum
of four years and be headquartered within North America.
Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited, a UK
private company limited by guarantee (“DTTL”), its network of member
firms, and their related entities. DTTL and each of its member firms are
legally separate and independent entities. DTTL (also referred to as
“Deloitte Global”) does not provide services to clients. In the United
States, Deloitte refers to one or more of the US member firms of DTTL,
their related entities that operate using the “Deloitte” name in the
United States and their respective affiliates. Certain services may not
be available to attest clients under the rules and regulations of public
accounting. Please see www.deloitte.com/about to
learn more about our global network of member firms.
Cautionary Note Concerning Forward-Looking Statements
This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995,
including, among others, statements regarding the capabilities and
anticipated utility of our GPS Cancer, including predicting patient
response and resistance to therapeutics, enabling diagnoses by
physicians and accelerating efforts to bring novel combinations of
therapeutic agents to cancer patients. Forward-looking statements are
subject to numerous risks and uncertainties that could cause actual
results to differ materially from currently anticipated results. Factors
that may cause future results to differ materially from management’s
current expectations include, among other things, that GPS Cancer may
not perform as anticipated, that sufficient physicians may not adopt GPS
Cancer to assist their diagnoses or that healthcare payers may not
provide reimbursement for GPS Cancer as expected. Our business is
subject to numerous additional risks and uncertainties, including, among
others, risks relating to market acceptance of our products; our ability
to successfully launch new products and applications; competition; our
sales, marketing and distribution capabilities; our planned sales,
marketing, and research and development activities; unanticipated
increases in costs or expenses; and risks associated with international
operations. Information on these and additional risks, uncertainties,
and other information affecting our business and operating results can
be found in our existing and future filings with the Securities and
Exchange Commission. These forward-looking statements speak only as of
the date hereof. We disclaim any obligation to update these
forward-looking statements except as may be required by law.
About NantHealth, Inc.
NantHealth, Inc., a member of the NantWorks ecosystem of companies, is a
next-generation, evidence-based, personalized healthcare company
enabling improved patient outcomes and more effective treatment
decisions for critical illnesses. NantHealth’s unique systems-based
approach to personalized healthcare applies novel diagnostics tailored
to the specific molecular profiles of patient tissues and integrates
this molecular data in a clinical setting with large-scale, real-time
biometric signal and phenotypic data to track patient outcomes and
deliver precision medicine. For nearly a decade, NantHealth has
developed an adaptive learning system, which includes its unique
software, middleware and hardware systems infrastructure that collects,
indexes, analyzes and interprets billions of molecular, clinical,
operational and financial data points derived from novel and traditional
sources, continuously improves decision-making and further optimizes our
clinical pathways and decision algorithms over time. For more
information please visit www.nanthealth.com and
follow Dr. Soon-Shiong on Twitter @DrPatSoonShiong.
About GPS Cancer™
GPS Cancer™ is a unique, molecular scan available through NantHealth.
GPS Cancer integrates whole genome (DNA) sequencing, whole transcriptome
(RNA) sequencing, and quantitative proteomics through mass spectrometry,
providing oncologists with a comprehensive molecular profile of a
patient’s cancer and an assessment of protein pathway function to inform
personalized treatment strategies. GPS Cancer scanning is conducted in
CLIA-certified and CAP-accredited laboratories, and is a key enabler for Cancer
Breakthroughs 2020, the world’s most comprehensive cancer
collaborative initiative seeking to accelerate the potential of
combination immunotherapy as the next generation standard of care in
cancer patients. For more information, visit www.gpscancer.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171115005473/en/
NantWorks
Jen Hodson
jhodson@nantworks.com
Source: NantHealth, Inc.